Published in Health Business Week, August 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at sanofi-aventis.
Report 1: Aventis announced today that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee did not recommend approval rimonabant (ZIMULTI(R)) to the use in obese and overweight patients with associated risks factors.
Sanofi-aventis will continue to work closely with the FDA to address the committee's recommendations.
The FDA has set a PDUFA action date of July 26, 2007 for rimonabant.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.